Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:51:58 UTC |
---|
HMDB ID | HMDB0015390 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Sitagliptin |
---|
Description | Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin. |
---|
Structure | N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 |
---|
Synonyms | Value | Source |
---|
(2R)-4-oxo-4-[3-(TRIFLUOROMETHYL)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine | ChEBI | MK-0431 | ChEBI | Sitagliptina | ChEBI | Sitagliptine | ChEBI | Sitagliptinum | ChEBI | Sitagliptan | HMDB | Sitagliptin phosphate | HMDB | 4-oxo-4-(3-(Trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine | HMDB | Anhydrous, sitagliptin phosphate | HMDB | Januvia | HMDB | Monohydrate, sitagliptin monophosphate | HMDB | Monohydrate, sitagliptin phosphate | HMDB | monoPhosphate monohydrate, sitagliptin | HMDB | Phosphate anhydrous, sitagliptin | HMDB | Phosphate monohydrate, sitagliptin | HMDB | Phosphate, sitagliptin | HMDB | Sitagliptin monophosphate monohydrate | HMDB | Sitagliptin phosphate anhydrous | HMDB | Sitagliptin phosphate monohydrate | HMDB |
|
---|
Chemical Formula | C16H15F6N5O |
---|
Average Molecular Weight | 407.3136 |
---|
Monoisotopic Molecular Weight | 407.118079357 |
---|
IUPAC Name | (3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one |
---|
Traditional Name | sitagliptin |
---|
CAS Registry Number | 486460-32-6 |
---|
SMILES | N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F |
---|
InChI Identifier | InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 |
---|
InChI Key | MFFMDFFZMYYVKS-SECBINFHSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Beta amino acids and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Beta amino acid or derivatives
- Amphetamine or derivatives
- Triazolopyrazine
- Fluorobenzene
- Halobenzene
- Aralkylamine
- Aryl fluoride
- Aryl halide
- Monocyclic benzene moiety
- Pyrazine
- Benzenoid
- 1,2,4-triazole
- Triazole
- Tertiary carboxylic acid amide
- Heteroaromatic compound
- Azole
- Carboxamide group
- Azacycle
- Organoheterocyclic compound
- Organic nitrogen compound
- Organohalogen compound
- Primary aliphatic amine
- Organic oxide
- Organopnictogen compound
- Organofluoride
- Carbonyl group
- Organic oxygen compound
- Amine
- Organonitrogen compound
- Alkyl halide
- Alkyl fluoride
- Hydrocarbon derivative
- Organooxygen compound
- Primary amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.034 g/L | Not Available | LogP | 1.5 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Sitagliptin,1TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 2794.4 | Semi standard non polar | 33892256 | Sitagliptin,1TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 2689.1 | Standard non polar | 33892256 | Sitagliptin,1TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 3168.4 | Standard polar | 33892256 | Sitagliptin,2TMS,isomer #1 | C[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C | 2943.9 | Semi standard non polar | 33892256 | Sitagliptin,2TMS,isomer #1 | C[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C | 2830.0 | Standard non polar | 33892256 | Sitagliptin,2TMS,isomer #1 | C[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C | 3020.6 | Standard polar | 33892256 | Sitagliptin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 3011.9 | Semi standard non polar | 33892256 | Sitagliptin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 2912.6 | Standard non polar | 33892256 | Sitagliptin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 3220.7 | Standard polar | 33892256 | Sitagliptin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C(C)(C)C | 3340.0 | Semi standard non polar | 33892256 | Sitagliptin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C(C)(C)C | 3256.8 | Standard non polar | 33892256 | Sitagliptin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C(C)(C)C | 3110.1 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Sitagliptin GC-MS (Non-derivatized) - 70eV, Positive | splash10-0295-2921000000-ee26b46d46fd47d93f77 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Sitagliptin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-QTOF , positive-QTOF | splash10-0a4i-0000900000-ce9211ae5927c697618c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-QTOF , positive-QTOF | splash10-052r-0690500000-c28779e719a0e517d106 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-QTOF , positive-QTOF | splash10-0076-0930000000-1337dd7fb10ab92722b5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-QTOF , positive-QTOF | splash10-00dl-0900000000-91485eb0052ad2f3637a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-QTOF , positive-QTOF | splash10-00di-0900000000-7d92431093315efaed86 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-000i-0390000000-c8853d370b51f01b194b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-0a4i-0000900000-2895dd4a879799635ae6 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-007c-0970100000-17431cd80097dff5c35f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-00dl-0910000000-29041ebd42cb7f6026df | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-00di-0900000000-dc60c3b1e5f0ba0e5e23 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-0umi-0900000000-b1e1f886377c8d9b2a5d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-004i-0900000000-d9e2b332d0ff3c6e283b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-0a4i-0000900000-3403c0e74f19a7d0832a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-007c-0970000000-6aa1fc14d171d0102a2c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-00dl-0910000000-62ba59074d19e0d89306 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-00di-0900000000-91600010aa7e80c0e67c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-0fmi-0900000000-d38f8b74df088a3b8232 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-004i-0900000000-08cf9f4ac284f2cd9057 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sitagliptin LC-ESI-ITFT , positive-QTOF | splash10-000i-0390000000-b6e5cd73f4ff7abd2747 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sitagliptin 10V, Positive-QTOF | splash10-0a4l-0427900000-7b4c67a1a8add9744953 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sitagliptin 20V, Positive-QTOF | splash10-0596-0921100000-2f2b7773685fbf5f2fab | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sitagliptin 40V, Positive-QTOF | splash10-0uka-3900000000-bce68660a46cc58a8e42 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sitagliptin 10V, Negative-QTOF | splash10-0a4i-0111900000-0b915943568998cafd46 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sitagliptin 20V, Negative-QTOF | splash10-0btl-0956400000-05e4d4efd040f50d1f3d | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sitagliptin 40V, Negative-QTOF | splash10-01tc-5910000000-603304da8956f43fb6ef | 2016-08-03 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01261 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01261 | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB01261 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 3571948 |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Sitagliptin |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 4369359 |
---|
PDB ID | 715 |
---|
ChEBI ID | 40237 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005 Dec;78(6):675-88. [PubMed:16338283 ]
- Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006 Aug;46(8):876-86. [PubMed:16855072 ]
- Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP: Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008 Feb;24(2):489-96. doi: 10.1185/030079908X261069 . [PubMed:18182122 ]
- Pratley RE, Salsali A: Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007 Apr;23(4):919-31. [PubMed:17407649 ]
- Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C: Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753-68. [PubMed:19065993 ]
- Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J, Krishna R: Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007 Sep;28(6):315-22. [PubMed:17575559 ]
|
---|